Pipeline Overview

Stabilized Injectable Formulation (SIF)

Product / Indication Research Pre-clinical Phase I Phase II Phase III NDA/MAA Market
CAMCEVI (Leuprolide, FP-001)
Prostate Cancer, CAMCEVI 42 mg
Prostate Cancer, CAMCEVI 42 mg
Prostate Cancer, CAMCEVI 21 mg
Prostate Cancer, CAMCEVI 21 mg
Central Precocious Puberty
Central Precocious Puberty
Premenopausal Breast Cancer
FP-014 (Triptorelin)
Prostate Cancer
FP-016 (Undisclosed)
Neurology; Psychiatry

New Chemical Entities (NCE)

Product / Indication Research Pre-clinical Phase I Phase II Phase III NDA/MAA Market
FP-025 (aderamastat, MMP-12 Inhibitor)
POC Phase 2 study in allergic asthma patients
Cardiac Sarcoidosis
Cardiac Sarcoidosis
FP-020 (linvemastat, MMP-12 Inhibitor)
Asthma or COPD
Asthma or COPD
Inflammatory bowel disease (IBD)
FP-MMP-12 inhibitor 1
ILD, including Idiopathic pulmonary fibrosis (IPF)
FP-MMP-12 inhibitor 2
Neurology
FP-045 (mirivadelgat, ALDH2 Activator)
POC Phase 1b/2 study in Fanconi Anemia (Pediatric formulation)
POC Phase 1b/2 study in Fanconi Anemia (Pediatric formulation)
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (solid formulation)
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (solid formulation)
FP-ALDH2 Activator 1
Cardiovascular, Renal and Metabolic Diseases (CVRM)
FP-ALDH2 Activator 2
Neurology